calendar
30 Mar, 2022
The company has obtained the EC approval from the Bellberry HREC Ethics Committee in Australia, for the first-in-human (FIH) clinical trial of GB263T, a novel EGFR/cMET/cMET trispecific therapeutic antibody, in patients with advanced Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.
2022
calendar
01 Mar, 2022
Genor Biopharma announced today that GB242 (infliximab) has received approval from China’s National Medical Products Administration (NMPA) for the treatment of Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, Adult Ulcerative Colitis, Adult and Pediatric Crohn's Disease and Fistulising Crohn’s Disease.
2019
calendar
30 Dec, 2021
With the theme of "Gathering Momentum and Making a New Start", the “2021 New Economic Trends Lists” were officially released. Genor Biopharma was included on the "2021 New Economy Most Valuable Listed Company" list.
2005
calendar
28 Dec, 2021
Genor Biopharma today announced the appointment of several world-renowned experts in tumor immunology & clinical oncology to its Scientific Advisory Board (SAB).
2000
calendar
22 Dec, 2021
Genor Biopharma (Stock code: 6998.HK) announced today that the company has submitted a clinical trial application to the Bellberry HREC Ethics Committee in Australia on December 20 for the first-in-human (FIH) clinical trial of GB263T, a novel EGFR/cMET/cMET trispecific therapeutic antibody, in patients with advanced malignant tumors.
1997